<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309647</url>
  </required_header>
  <id_info>
    <org_study_id>106378</org_study_id>
    <nct_id>NCT00309647</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Immunogenicity of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) in Adults 18 and 60 Years of Age</brief_title>
  <official_title>A Partially-blind Multi-centric Study in Adults Aged Between 18-60 Years Designed to Evaluate the Reactogenicity and Immunogenicity of 1 and 2 Doses of Pandemic Monovalent (H5N1) Influenza Vaccines (Whole Virus Formulation) Administered at Different Doses and Adjuvanted or Not</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian&#xD;
      virus. Prevention and control of a pandemic will depend on the rapid production and worldwide&#xD;
      distribution of specific pandemic vaccines. Candidate 'pandemic-like' vaccines must be&#xD;
      developed and tested in clinical trials to determine the most optimal formulation and the&#xD;
      best vaccination schedule.This study is designed to test in healthy adults aged between 18-60&#xD;
      years the reactogenicity and immunogenicity of one and two administrations of a candidate&#xD;
      pandemic H5N1 vaccine formulated from Whole Virus. The vaccines contain different antigen&#xD;
      doses. For each dose, adjuvanted vaccine will be compared to the plain vaccine in order to&#xD;
      detect the optimal formulation for immunization against the H5N1 influenza strain.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 29, 2006</start_date>
  <completion_date type="Actual">November 16, 2006</completion_date>
  <primary_completion_date type="Actual">November 1, 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the humoral immune response induced by the study vaccines in term of anti-haemagglutinin antibody titers</measure>
    <time_frame>At Days 0, 21, 42 and 180</time_frame>
    <description>Geometric mean titers (GMTs) of serum antibodies</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To evaluate the humoral immune response induced by the study vaccines in terms of seroconversion rates (SCRs), Conversion factors and protection rates to H5N1 virus</measure>
    <time_frame>At days 21, 42 and 180</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of solicited local and general adverse events</measure>
    <time_frame>During a 7 day follow-up period (i.e. day of vaccination and 6 subsequent days) after each dose of vaccine and overall</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of unsolicited adverse events</measure>
    <time_frame>During a 21 day follow-up period after the first vaccination and 30 day follow-up period after the second vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence of serious adverse events</measure>
    <time_frame>During the entire study (Days 0 to 180)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the humoral immune response induced by the study vaccines in term of serum neutralizing antibody titers</measure>
    <time_frame>At Days 0, 21, 42 and 180</time_frame>
    <description>Geometric mean titers (GMTs) of serum antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the cell-mediated immune response induced by the study vaccines in term of frequency of influenza-specific CD4/CD8 T lymphocytes</measure>
    <time_frame>At days 0, 21, 42 and 180</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the humoral immune response induced by the study vaccines in terms of SCR for serum neutralizing antibody titers</measure>
    <time_frame>At Days 21, 42 and 180</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>H5N1 Formulation 1 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 adjuvanted formulation 1 vaccine at a 21-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 Formulation 2 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 adjuvanted formulation 2 vaccine at a 21-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 Formulation 3 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 adjuvanted formulation 3 vaccine at a 21-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 Formulation 4 Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 adjuvanted formulation 4 vaccine at a 21-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 Formulation 5 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 formulation 5 vaccine at a 21-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 Formulation 6 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 formulation 6 vaccine at a 21-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 Formulation 7 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 formulation 7 vaccine at a 21-day interval</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H5N1 Formulation 8 Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 2 doses of H5N1 formulation 8 vaccine at a 21-day interval</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine</intervention_name>
    <description>2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21</description>
    <arm_group_label>H5N1 Formulation 1 Group</arm_group_label>
    <arm_group_label>H5N1 Formulation 2 Group</arm_group_label>
    <arm_group_label>H5N1 Formulation 3 Group</arm_group_label>
    <arm_group_label>H5N1 Formulation 4 Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenza Monovalent Whole virus (H5N1)</intervention_name>
    <description>2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21</description>
    <arm_group_label>H5N1 Formulation 5 Group</arm_group_label>
    <arm_group_label>H5N1 Formulation 6 Group</arm_group_label>
    <arm_group_label>H5N1 Formulation 7 Group</arm_group_label>
    <arm_group_label>H5N1 Formulation 8 Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  A male or female between, and including, 18 and 60 years of age at the time of the&#xD;
             first vaccination.&#xD;
&#xD;
          -  Healthy subjects as established by medical history and clinical examination before&#xD;
             entering into the study.&#xD;
&#xD;
          -  If the subject is female, she must be of non-childbearing potential.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Administration of any vaccine during the period starting 15 days before the first&#xD;
             administration of the study vaccine and ending 21 after the second one.&#xD;
&#xD;
          -  Administration of an influenza vaccine other than the study vaccines during the entire&#xD;
             study period.&#xD;
&#xD;
          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other&#xD;
             immune-modifying drugs within six months prior to the first administration of the&#xD;
             study vaccine.&#xD;
&#xD;
          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on&#xD;
             medical history and physical examination&#xD;
&#xD;
          -  History of hypersensitivity to vaccines.&#xD;
&#xD;
          -  History of allergic disease or reactions likely to be exacerbated by any component of&#xD;
             the vaccine.&#xD;
&#xD;
          -  Acute clinically significant pulmonary, cardiovascular, hepatic or renal functional&#xD;
             abnormality, as determined by physical examination or laboratory screening tests.&#xD;
&#xD;
          -  Acute disease at the time of enrolment.&#xD;
&#xD;
          -  Administration of immunoglobulins and/or any blood products within the three months&#xD;
             preceding the first administration of the study vaccine or during the study.&#xD;
&#xD;
          -  lactating women&#xD;
&#xD;
          -  Use of any investigational or non-registered product (drug or vaccine) other than the&#xD;
             study vaccine(s) within 30 days prior to the first vaccination, or planned use during&#xD;
             the study period.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Finsterwalde</city>
        <state>Brandenburg</state>
        <zip>03238</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tostedt</city>
        <state>Niedersachsen</state>
        <zip>21255</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01129</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Freiberg</city>
        <state>Sachsen</state>
        <zip>09599</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geringswalde</city>
        <state>Sachsen</state>
        <zip>09326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Schmiedeberg</city>
        <state>Sachsen</state>
        <zip>01762</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Segeberg</city>
        <state>Schleswig-Holstein</state>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Elmshorn</city>
        <state>Schleswig-Holstein</state>
        <zip>25335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>March 31, 2006</study_first_submitted>
  <study_first_submitted_qc>March 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>May 5, 2017</last_update_submitted>
  <last_update_submitted_qc>May 5, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prophylaxis of pandemic influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

